BridgeMD
New treatment option for Infertility
Official title Hyaluronan-enriched Medium and Euploid Blastocyst Transfers
ClinicalTrials.gov ID: NCT06165367
What this study is testing
What is EmbryoGlue Medium?
EmbryoGlue Medium is an investigational medicine, being studied as a potential treatment for infertility.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule. However, none of previous studies included preimplantation genetic testing for aneuploidy (PGT-A) embryos.
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 46, women only. Healthy volunteers may be eligible.
You may be able to join if
- All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.
- Rank of randomization based on embryo quality.
- Only hormonal replacement theraphy (HRT) cycle regimen.
- Women aged 18 years to 46 years.
- Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.
You likely can't join if
- FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).
- FET cycles with mosaic / aneuploid blastocysts.
- FET cycles with unknown outcome.
- FET cycles with Day 6 or Day 7 biopsied blastocysts.
- FET with patients' endometrium preparation with treatments other than HRT.
- FET where PGT-A was performed for gender selection.
See the full eligibility criteria
- All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.
- Rank of randomization based on embryo quality.
- Only hormonal replacement theraphy (HRT) cycle regimen.
- Women aged 18 years to 46 years.
- Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.
- All sperm samples.
- BMI between 18 and 35.
- FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).
- FET cycles with mosaic / aneuploid blastocysts.
- FET cycles with unknown outcome.
- FET cycles with Day 6 or Day 7 biopsied blastocysts.
- FET with patients' endometrium preparation with treatments other than HRT.
- FET where PGT-A was performed for gender selection.
The study team makes the final eligibility decision.
Where it's taking place
- Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 46 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.